BioNexus Gene Lab (NASDAQ:BGLC) Earns “Sell (E+)” Rating from Weiss Ratings

BioNexus Gene Lab (NASDAQ:BGLC)‘s stock had its “sell (e+)” rating reissued by Weiss Ratings in a report issued on Thursday,Weiss Ratings reports.

BioNexus Gene Lab Stock Up 4.4%

Shares of BGLC opened at $5.42 on Thursday. BioNexus Gene Lab has a 52-week low of $2.01 and a 52-week high of $15.60. The company has a market capitalization of $9.76 million, a PE ratio of -9.51 and a beta of 5.20. The stock has a fifty day simple moving average of $5.33 and a two-hundred day simple moving average of $4.52.

BioNexus Gene Lab (NASDAQ:BGLC) last issued its earnings results on Monday, August 18th. The company reported ($0.34) earnings per share (EPS) for the quarter. BioNexus Gene Lab had a negative return on equity of 35.54% and a negative net margin of 30.70%.The company had revenue of $2.26 million during the quarter.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.